This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Autret, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Autret, E.
Related Collections
Right arrow Therapeutics & Toxicology

PEDIATRICS Vol. 104 No. 3 Supplement September 1999, pp. 614-618

European Regulatory Authorities and Pediatric Labeling

Elisabeth Autret, MD

From Hôpital Bretonneau, Pharmacologie Clinique, Tours, France.

The first 300 words of the full text of this article appear below.

    CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN CHILDREN

The Need for Medicinal Product Testing in Children

Ethical Considerations Children should not be given medicines that have not been evaluated adequately for use in that age group. There is a responsibility, shared by applicants and the appropriate authorities, to ensure that children have timely access to safe and effective medicines that have accurate, scientifically justified prescribing information. Applicants are encouraged to investigate the safety and efficacy of a product in children, if it is likely to be of therapeutic benefit in this age-group, and to develop suitable formulation, even if use is likely to be small.

However important a clinical trial may be to prove or disprove the value of a treatment, individual members of one or both of the groups---subject or control---can suffer injury as a result of inclusion in the trial, even if the whole community benefits. As with adults who participate in clinical trials and who understand the issues involved in giving their informed consent, consent should be obtained from the legal guardian of children in accordance with national legislation. Children should be fully informed about the trial in language and terms they understand and, if able, should personally sign and date the written informed consent. The child should be made aware of his/her rights to decline to participate. The child's wish to be withdrawn from a study must be respected.

These measures should be applied in conjunction with 1) part 4 of Directive 75/318/EEC, as amended, which requires "... details concerning patients who may be at increased risk"; the CPMP/ICH guideline for good clinical practice; and 3) the CPMP guideline on biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products.

These measures are intended to assist applicants with specific problems presented by medicinal product testing in children. The child should . . . [Full Text of this Article]


This article has been cited by other articles:


Home page
 PediatricsHome page
E. Schirm, H. Tobi, and L. T.W. de Jong-van den Berg
Risk Factors for Unlicensed and Off-Label Drug Use in Children Outside the Hospital
Pediatrics, February 1, 2003; 111(2): 291 - 295.
[Abstract] [Full Text] [PDF]